Jeffrey Weber, MD, PhD, NYU Langone Medical Center, New York City, NY, outlines the new ASCO guidelines on the management of immune-related adverse events in patients treated with immune checkpoint inhibitor (ICI) therapy. ICI therapy should initially be closely monitored for Grade 1 toxicities except for some neurologic, hematologic, and cardiac toxicities, and should be suspended for most Grade 2 and 3 toxicities and started again when side effects revert to Grade 1. Whilst corticosteroids may be used, they should be gradually reduced over the course of 4-6 weeks and other alternative immunosuppressive therapies should be offered to steroid-refractory patients. ICIs should be permanently discontinued in patients experiencing Grade 4 toxicities. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.